Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disorder with a complex pathology that is not completely understood. Over time, AD reduces one’s cortical and subcortical functioning. The incidence and prevalence of AD is projected to increase as the worldwide population continues to grow older. While advances in the field of neurology and medicine continue to improve, there are presently no novel therapeutic agents to prevent, halt, or cure patients suffering from AD. The utilization of biomarkers that aid the diagnostic algorithm, drug response monitoring and disease progression that add to further our understanding of the pathophysiology of neurodegenerative disease is vastly expanding. The significance of amyloid plaque deposition, tau pathology, and neurofibrillary tangle accumulation have been well-studied in the realm of neurodegenerative diseases for decades and are proposed biomarkers. However, it has been difficult to stratify physiological biomarkers of blood/plasma, cerebrospinal fluid, saliva/urine/hair/nail for diagnostic utility and overall understanding in the pathogenesis of neurodegeneration. We aim to review the most relevant, up-to-date biomarkers and their implications in AD.
relates with increased oxidative stress from neural free radical production. Mitochondrial dysfunction, calcium-mediated excitotoxicity, vascular injury, and immuno-dysregulation also appear to contribute to the development and/or exacerbation of AD. These pathologies cause a neuronal cellular insult, resulting in impaired synaptic function, as well as an overall reduction in healthy functioning neural tissue. The resulting chronic neurodegenerative changes produce cognitive, behavioral, and functional abnormalities that manifest as memory deterioration, confusion, and difficulty understanding visual and spatial relationships amongst many other clinical signs and symptoms.

It has become an urgent priority within the medical community to identify biological markers and blood testing protocols to better understand the pathogenesis of AD in order to improve the efficiency of diagnosis, reduce associated costs, and prevent the occurrence of neurodegenerative diseases. Several methods have been previously deployed for aiding in the diagnostic algorithm of AD, including positron emission tomography (PET) scans to measure amyloid plaque deposits, lumbar punctures directed towards quantifying the degree of tau protein in the cerebrospinal fluid (CSF), and analyzing the amount of cortical atrophy via magnetic resonance imaging (MRI). However, imaging to this degree is very costly and measuring protein levels within the CSF is an invasive procedure.

Herein, we review the contributions made towards the relevance in blood testing and biomarker identification in the use for diagnosing AD. We discuss the current roles and propose future uses for biomarkers in improving diagnostic accuracy, cost efficiency, patient stratification, and monitoring disease staging and progression to novel treatments for AD. The focus of this review article is to improve our overall depth of comprehension of the role biomarkers play in understanding the pathogenesis and treatment of AD.

Pathogenesis and pathology

The pathogenesis and pathology of AD is important when discussing implicated biomarkers. Although the pathology is not clear, the leading theory is that there is an accumulation of insoluble Aβ peptides. Amyloid precursor protein (APP) is a transmembrane glycoprotein that is physiologically cleaved by alpha and gamma secretases to form two physiologic proteins, one soluble and one membrane bound. In the amyloid-producing process, APP is enzymatically cleaved by beta and gamma secretases, leading to the formation of various isoforms of Aβ peptides. These peptides aggregate to form fibrils and oligomers, ultimately leading to Aβ plaque formation. This eventually leads to inflammation and neuronal cell death, a process known as the amyloid cascade hypothesis. Consequently, these neuritic plaques can be observed via microscopy of brain tissue from AD patients, along with neuronal synapse loss.

Another protein involved in the suggested pathogenesis of AD is tau. Tau is an axonal, microtubule-associated protein (MAP) that regulates the assembly and function of microtubules, predominantly within neurons. Physiologically, tau is highly soluble and undergoes phosphorylation to regulate its microtubule binding affinity. In AD, tau is hyper-phosphorylated, forming an insoluble protein that aggregates into toxic NFTs within neurons. These NFTs are another characteristic pathological feature found in the brains of AD patients. Furthermore, it is thought that tau has a role in mediating Aβ toxicity in AD, though this mechanism is unclear.

Additionally, there are several genes implicated in the development of AD, one of the most notable being the e4 allele of the apolipoprotein E gene (APOE). APOE plays a role in Aβ peptide clearance, and individuals with the e4 allele are at an increased risk of AD, most likely due to Aβ accumulation through unclear mechanisms. In rare cases, genetic mutations of APP or presenilin (PSEN) genes can be inherited in an autosomal dominant pattern that results in an early onset AD. PSEN is a protein in the enzymatic gamma secretase complex that is responsible for pathological cleavage of APP in the development of AD.

Biological markers (biomarkers)

A biomarker is a metric of a particular biological state that can be quantified or measured. A biomarker may be used to evaluate normal physiological processes within the body, pathological processes, or a pharmacological response to medical intervention. Biomarkers have played valuable roles in the diagnostic algorithm of many diseases, as well as the assessment of disease progression and potential recurrence. What makes a biomarker such a useful tool for researchers and clinicians is the ability to detect a fundamental neuropathologic feature of AD and with a relatively high sensitivity and specificity (ability of a test to accurately identify individuals with versus without a disease).

There have been many biomarkers identified within the human body that serve as valuable tools in diagnosing and monitoring AD progression. Table 1 summarizes the biomarkers that are covered in this review and demonstrates the relevant changes associated in AD. Below is a comprehensive review of the biomarkers that have been identified and used in the diagnosis and treatment of AD. An illustrative overview of the pathological mechanisms covered in this paper are presented in Figure 1.

Cerebrospinal fluid (CSF) biomarkers

The most widely studied CSF biomarkers related to neurodegenerative diseases are Aβ peptides, and in particular the Aβ42 protein, total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau181). These biomarkers exhibit greater than 95% sensitivity and 85% specificity in regards to diagnosing AD. Low quantities of Aβ42 in the CSF are observed in AD individuals compared to controls, while elevated levels of hyper-phosphorylated tau and t-tau have been identified in the CSF in AD patients. Previous literature has shown that high t-tau and/or p-tau181 along with low Aβ42 in the CSF can be detected before patients with AD become symptomatic, and offer improved diagnostic accuracy of AD from other causes of dementia. The ratio of t-tau/Aβ42 or p-tau181/Aβ42 within the CSF are reliable predictors in the progression of AD and in determining future cognitive impairment in individuals without a current neurological deficit over a 10-year follow-up period.

Amyloid (Aβ) peptides

Aβ peptides are formed after being cleaved from amyloid precursor proteins. The Aβ peptides are then released into the CSF. This biological process allows for the level of Aβ peptides to be measured fairly easily. It has been well documented that a low level of Aβ42 peptides in the CSF and a high amyloid plaque concentration in the brain are highly suggestive of AD. The pathogenesis of the diminished Aβ42 peptides in the CSF is a result of the aggregation of hydrophobic peptide-forming plaques. A reduced level of Aβ42 has also been noted in patients with Lewy body demen-
Enzyme-linked immunosorbent assay (ELISA) and mass spectrometry have been utilized for accurately measuring CSF levels of Aβ42 peptides.\(^{24,36}\) It has been identified that measuring Aβ peptide ratios may be advantageous over measuring the total Aβ42 peptide levels within the CSF. CSF measurements of Aβ42/Aβ40 and Aβ42/Aβ40 have proven to be of minimal reliability when diagnosing AD.\(^{23,35}\)

Measuring the CSF level of shortened Aβ peptides (Aβ38 and Aβ40) has proven to be of minimal reliability when diagnosing AD.\(^{23,35}\) It has been identified that measuring Aβ peptide ratios may be advantageous over measuring the total Aβ42 peptide levels within the CSF.

### Table 1. Comprehensive list of the biomarkers identified within the CSF and blood plasma, noting the relative changes in AD patients

| Pathological mechanism | Biomarker | Elevated levels in CSF | Reduced levels in CSF | Elevated levels in plasma | Reduced levels in plasma |
|------------------------|-----------|------------------------|-----------------------|--------------------------|--------------------------|
| Amyloid                | Aβ42      | X                      | X                     | X                        | X                        |
|                        | Aβ40      | X                      | X                     |                          |                          |
|                        | Aβ38      | X                      | X                     |                          |                          |
| Tau                    | p-tau     | X                      | X                     |                          |                          |
|                        | t-tau     | X                      |                       |                          |                          |
| Amyloid precursor      | BACE1     | X                      |                       |                          |                          |
| Synapse                | Ng        |                        | X                     |                          |                          |
|                        | SNAP25    |                        | X                     |                          |                          |
|                        | Syt1      |                        | X                     |                          |                          |
|                        | GAP43     |                        | X                     |                          |                          |
|                        | NPTX/NP   |                        | X                     |                          |                          |
| Neuronal               | NfL       | X                      | X                     |                          |                          |
|                        | VILIP1    |                        |                       |                          |                          |
| Vascular               | VCAM1     | X                      | X                     |                          |                          |
|                        | ICAM1     |                        | X                     |                          |                          |
|                        | Flt1      |                        | X                     |                          |                          |
|                        | ANP       |                        |                       | X                        |                          |
|                        | ADM       |                        | X                     |                          |                          |
|                        | ET1       |                        |                       |                          | X                        |
| Inflammatory           | IL6       | X                      |                       |                          |                          |
|                        | IL15      |                        | X                     |                          |                          |
|                        | IL18      |                        |                       | X                        |                          |
|                        | sIL1R2    |                        |                       |                          | X                        |
|                        | hFABP     |                        | X                     |                          |                          |
|                        | TNFa      |                        | X                     |                          |                          |
|                        | TREM2     |                        | X                     |                          |                          |
|                        | YKL40     |                        | X                     |                          |                          |
|                        | GFAP      |                        |                       |                          |                          |
|                        | S100B     |                        |                       |                          |                          |
| DNA binding            | TDP43     |                        |                       | X                        |                          |
| Metabolites            | PUFA      |                        |                       |                          | X                        |
|                        | Bile acids|                        |                       |                          | X                        |
|                        | Tryptophan|                        |                       |                          | X                        |
| Iron                   | Ferritin  |                        |                       |                          | X                        |

Aβ, Amyloid beta; ADM, Adrenomedullin; ANP, Atrial natriuretic peptide; BACE1, β-secretase 1; ET1, Endothelin-1; Flt1, fms-related receptor tyrosine kinase; GAP43, Growth-associated protein-43; GFAP, Glial fibrillary acidic protein; hFABP, heart-type fatty acid-binding protein; ICAM1, Intercellular adhesion molecule 1; IL, Interleukin; NfL, Neurofilament-light chain; Ng, Neurergusin; NPTX, Neuronal pentraxins; p-tau, Phosphorylated tau; PUFA, Polysaturated fatty acid; S100B, S100 calcium-binding protein B; sIL1R2, Soluble interleukin-1 receptor 2; SNAP25, Synaptosome-associated protein-25; Syt1, synaptotagmin-1; TDP, TAR-DNA binding protein; TNFa, Tumor necrosis factor alpha; TREM2, Triggering receptor expressed on myeloid cells 2; t-tau, Total tau; VCAM1, Vascular cell adhesion protein 1; VILIP1, Visinin-like protein 1; YKL40, Chitinase-3-like protein 1.

\(^{24,36}\) Enzyme-linked immunosorbent assay (ELISA) and mass spectrometry have been utilized for accurately measuring CSF levels of Aβ42 peptides.\(^{34,38}\)

Measuring the CSF level of shortened Aβ peptides (Aβ38 and Aβ40) has proven to be of minimal reliability when diagnosing AD.\(^{23,35}\) It has been identified that measuring Aβ peptide ratios may be advantageous over measuring the total Aβ42 peptide levels within the CSF.
Aβ38 ratios were shown to better differentiate AD from dementia of a non-AD cause. The ratios are more closely associated with overall amyloid plaque deposition on PET scans and may be a superior target measure for newly implemented clinical trials of amyloid-based treatments than of CSF Aβ42 alone.²,³⁹,⁴⁰ A limiting factor of measuring only Aβ42 is the potentially confounding effect that results from differences in CSF subtleties or the variable rate of amyloid production from person to person. Importantly, this limitation is corrected when using the CSF Aβ42/Aβ40 ratio instead.²,⁴¹ When CSF Aβ42 is measured in conjunction with CSF Aβ40, it provides a useful measure for target engagement of β-secretase (BACE1) modulators to inhibit Aβ peptide production and deposition.⁴² There have also been promising results in tracking the physiological response to treatment with γ-secretase inhibitors when low CSF Aβ42 and Aβ40 levels are found with increased amounts of shortened fragments of CSF Aβ37 and Aβ38.⁴³

Phosphorylated Tau (p-tau)

NFTs are composed of aggregates of abnormally hyper-phosphorylated p-tau.²,³⁴,⁴⁴ Excessive amounts of p-tau in the CSF have been widely documented in AD patients, and are associated with an increased rate of disease progression.³⁴,⁴⁵,⁴⁶ The hyper-phosphorylation of these proteins results in the dysfunction of axonal transport in the brain.⁴⁷ ELISA offers an effective way to measure p-tau by recognizing specific epitopes.⁴⁵ Tau proteins phosphorylated at threonine 181 (p-tau181) have been the most thoroughly studied form of tau in conjunction with neurodegenerative disease.²,³⁴,⁴⁴,⁴⁵ However, recent literature that has studied p-tau231 and p-tau199 levels in the CSF confirmed a similar specificity to p-tau181 in differentiating AD from healthy controls.⁴⁸ Furthermore, p-tau231 demonstrated high sensitivity and specificity as a reliable biomarker for differentiating AD from non-AD dementias.⁴⁸ A study completed in 2020, found elevated levels of tau phosphorylated at threonine 217 (p-tau217) in the CSF of patients with AD and proved to more accurately differentiate AD from non-AD dementias than CSF p-tau181.⁴⁹ In the same study, a higher level of p-tau217 in the CSF demonstrated a closer correlation with the measured amount of cortical amyloid present on PET scans and in the CSF compared to that of p-tau181.⁴⁹ Lastly, baseline and longitudinal measurements of CSF p-tau217 correlated with cortical tau deposition to a better extent than CSF p-tau181 when measured by the PET tau tracer [18F] flortaucipir.⁴⁹ Several other p-tau proteins have also been studied (235, 396, and 404) that may be of value as potential biomarkers after further research is performed to identify neurodegenerative disease states in the future.⁵⁰

Total Tau (t-tau)

T-tau is utilized as an indicator for overall neurodegeneration.⁵¹
In healthy individuals, CSF t-tau increases with age: <300 pg/ml (21–10 yrs), <450 pg/ml (51–10 yrs), and <500 pg/ml (>70 yrs). CSF t-tau has also been found to be significantly elevated in AD patients when compared to age-matched controls (>600 pg/ml in AD patients >70 yrs). The t-tau level in the CSF is also potentiated as a prognostic marker for the conversion of mild cognitive impairment (MCI) to AD. High CSF t-tau levels have been found in over 90% of patients diagnosed with MCI that progressed to early-onset AD symptoms. CSF t-tau can be measured using ELISA.

Beta site-amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)

BACE1 is a major β-secretase involved in plaque formation in the brain. BACE1 expression is influenced by an inflammatory state, and in AD, the upregulation of neuritic cytokines reduces the peroxisome proliferator-activated receptors (PPAR1) which acts as an inhibitor of BACE1. CSF levels of BACE1 have been previously measured by Western blot and ELISA in both MCI and AD patients, as well as healthy controls. Along these lines, a significantly increased level of CSF BACE1 was found in MCI subjects versus AD and healthy controls. The high BACE1 level in the CSF of MCI patients may reflect an overproduction of BACE1 by stressed neurons and/or glial cells in MCI, which then decreases while cells die during the progression to AD. Nevertheless, further analysis is needed before BACE1 can be considered a reliable CSF biomarker for AD.

Synaptic biomarkers

A synapse or neuronal junction is the site of transmission of electrical impulses between neurons (nerve cells) or between a neuron and a gland or muscle cell. A synapse functions by storing neurotransmitters in presynaptic vesicles that are then released into the inter-neural space or synaptic cleft. This process allows communication with synaptophysin and SNAP25.

Another important pre-synaptic biomarker found in the CSF of AD patients is Syt1. This protein acts as a calcium sensor to allow neurotransmitter release into the synaptic cleft. Increased amounts of Syt1 levels were identified in the CSF in the early stages of AD and MCI compared to healthy controls when using mass spectrometry. A similar study concerning CSF biomarkers found low reliability in differentiating MCI due to AD and AD dementia when CSF Syt1 was compared to CSF levels of Ng and SNAP25a. The use of Syt1 needs more validation through future studies before being considered a reliable CSF biomarker for neurodegenerative diseases.

A lesser-studied CSF biomarker in AD is growth-associated protein-43 (GAP43, neuromodulin). GAP43 is a crucial component of the neuronal axon and presynaptic terminal, and is primarily responsible for growth or “synaptic plasticity”. This protein also functions in pre-synaptic vesicle recycling through communication with synaptophysin and SNAP25. A strong association has been found with increased GAP43 levels in the CSF with amyloid and p-tau/t-tau in AD patients, as well as most other neurodegenerative conditions. This biomarker may have strong potential for use in the diagnostic algorithm of neurodegenerative disease.

Pre-synaptic glycoproteins, often referred to as neuronal pentraxins (NPTX, NP) are involved in excitatory synapse formation of α-amino-3-hydroxy-5-methyl-4-isoxazolopropionic acid (AMPA) and are responsible for apoptotic neuronal death. Amyloid oligomers induce the pre-synaptic release of NP1, which is partially responsible for the synaptic and mitochondrial insult seen in the amyloid pathology of neurodegeneration. Previous studies have correlated higher CSF levels of the pentraxin receptor, with increased severity of dementia in patients suffering from early-onset AD symptoms. Current information available regarding the usefulness of neuronal pentraxins as CSF biomarkers of synaptic injury is inadequate, and further research is necessary.

Neuronal biomarkers

A neuron is a highly specialized cell within the nervous system that is composed of several unique structures that include dendrites, a cell body and an axon. Few neuron-specific biomarkers have been studied in depth, however, the most relevant neuronal biomarkers found in the CSF include neurofilament-light chain (NFL) and visinin-like protein 1 (VILIP1). NFL is a measurable component of the CSF when using immuno-
neuroassay. This marker is largely found within neuron axons and can be used to evaluate axonal damage in many neurological disorders. Elevated levels of CSF NfL may offer another reliable biomarker for grading AD severity and progression. Research has revealed elevated levels of NfL in the CSF during the early stages of symptom onset in AD. Furthermore, rising levels of CSF NfL have been associated with the degree of cortical atrophy, cognitive impairment, and overall death rate of AD.

VILIP1 is a protein that is expressed in abundance within the cerebellum and functions as a calcium-sensing receptor that is responsible for controlling intracellular signaling pathways through its regulation of adenylyl cyclase. This receptor is also a strong correlation between the level of VILIP1 in the CSF and overall cortical atrophy, as well as with amyloid/t-tau levels in patients displaying varying degrees of AD progression. Similar to other CSF biomarkers, VILIP1 levels were increased in patients with MCI as a result of AD, in addition to individuals with AD dementia, when compared to healthy controls. The ratio of CSF VILIP1/Ab42 may serve as a better marker for determining whole-brain or regional cortical atrophy and cognitive deterioration when evaluated against some of the most widely studied CSF biomarkers that include t-tau, p-tau181, Ab42 and t-tau/Ab42 or p-tau181/Ab42. CSF VILIP1 has been determined to be a promising marker for not only neuronal injury in AD, but also as a reliable marker of future impairment in patients who are intellectually normal.

**Vascular markers of the CSF**

Vascular injury and insult have provided some promising potential CSF biomarkers regarding neurodegenerative disease. Some of the previously identified vascular CSF biomarkers include vascular cell adhesion protein 1 (VCAM1), which mediates the binding of immune cells when endothelial damage occurs inside of blood vessels, intercellular adhesion molecule 1 (ICAM1), a protein present on the surface of leukocytes that is responsible for cellular-vessel wall adhesion, interleukin-15 (IL15), a pro-inflammatory cytokine, and fms-related receptor tyrosine kinase (Flt1), a transmembrane domain responsible for angiogenic growth factor binding. A 2018 study demonstrated increased CSF level of VCAM1, ICAM1, IL15 and Flt1 in patients diagnosed with AD in symptomatic and pre-symptomatic states when compared to healthy controls. Adhesion proteins (ICAM1 and VCAM1) were also found to be strongly associated with future cognitive decline.

A cytoplasmic cardiac protein called heart-type fatty acid-bind- ing protein (hFABP), which is released during periods of myocardial ischemia, has been isolated in the CSF at elevated levels in patients with AD and vascular dementia. An increased level of hFABP in the CSF is also correlated with lower CSF Ab42 as well as cortical deterioration in patients who displayed amyloid plaque accumulation. This may therefore be a potentially useful marker in distinguishing characteristics between vascular dementia, AD and other forms of neurodegeneration.

**Cytokines and Inflammatory mediators**

Neuro-inflammation is recognized as a fundamental component in the pathological process observed in AD. For over forty years, literature has indicated protective effects against AD when patients take anti-inflammatory agents for various other unrelated diseases. Research hypothesizes the overwhelmingly increased deposition of Aβ plaques and a prolonged inflammatory response in an attempt to combat this pathology. The results indicate a sustained activation of microglia in a feed-forward loop that causes inevitable progression of the disease.

Tumor necrosis factor-alpha (TNFa) is a small signaling protein (cytokine) released from microglial cells and astrocytes in the brain in response to an inflammatory reaction. CSF levels of TNFa, as well as TNFa converting enzyme (TACE), have been found to be higher in AD patients when compared to healthy controls. Another well-studied inflammatory biomarker is triggering receptor expressed on myeloid cells 2 (TREM2). Research has described missense mutations of TREM2, which induces phagocytosis of amyloid plaques, as a significant risk for the development of AD and other neurodegenerative diseases. There have been similar reports from animal studies and human models that have identified elevated CSF levels of TREM2 in pre-symptomatic stages of AD patients. Recent literature also suggests that CSF TREM2 levels may be directly associated with the degree of tau and/or amyloid pathology present. An astrocytic pro-inflammatory biomarker called chitinase-3-like protein 1 (YKL40) has been studied to assess the diagnostic accuracy in the CSF of AD patients. In a study focusing on CSF YKL40 levels, researchers were able to positively discriminate AD from cognitively normal controls and patients with frontotemporal dementia (FTD). Furthermore, this same study found that the CSF level of YKL40 appropriately identified tau-positive individuals and AD pathophysiology-positive individuals from healthy controls and FTD patients. Increased levels of CSF YKL40 have shown a positive correlation with cortical thinning in AD patients who displayed the APOE4 mutation. CSF YKL40 has been positively associated with tau protein during the asymptomatic and preclinical stages of AD. YKL40 may also serve as a reliable biomarker for future cognitive decline. The utilization of CSF YKL40 as a biomarker in neurodegenerative diseases adds to the growing array of markers used for understanding and treating these diseases.

Glial fibrillary acidic protein (GFAP) is an intermediate filament expressed in astrocytes and ependymal cells throughout the central nervous system. Increased CSF levels of GFAP have been identified in several neurodegenerative diseases, including AD, FTD and Lewy body dementia. Another potentially useful biomarker is S100 calcium-binding protein B (S100B). This protein is exclusively expressed in astrocytes and has several theorized functions, such as neurite expansion and growth. Elevated CSF S100B levels may offer diagnostic value during the initial stages of AD, especially when evaluating short-term memory recall.

**Blood and Plasma Biomarkers**

**Amyloid (Aβ) peptides**

Detecting Aβ in plasma and accurately using it as a biomarker for amyloid pathology has been difficult using ELISA. Not only are plasma Aβ levels much lower than in the CSF, but there is also a poor correlation between CSF and plasma levels of Aβ alone. For this reason, and due to the contribution of Aβ from other peripheral sources, there has been inconsistency in plasma measurements of Aβ in different laboratories using ELISA. This aside, one study showed that decreasing levels of Ab42, an Aβ peptide with 42 residues that contributes to plaque formation, and decreasing ratios of Ab42/Ab40 in serial measurements using ELISA were associated with cognitive decline and the development of AD. DOI: 10.14218/ERHM.2021.00016 | Volume 00 Issue 00, Month Year
The past decade has exhibited improvements in accurate measurements of Aβ using immunoaffinity-based assays, including single-molecule arrays (SIMOA) and mass spectrometry. Specifically, studies using these methods to measure Aβ42/Aβ40 or Aβ40/Aβ42 ratios in plasma have shown a correlation with AD pathology, suggesting that it can serve as a prognostic indicator. Plasma levels of Aβ42/Aβ40 were additionally able to predict amyloid pathology in patients without cognitive decline who were at risk for AD. Recent studies have used immunoprecipitation and mass spectrometry to test for plasma biomarkers in both cognitively normal and abnormal patients. These works showed that there is a strong correlation between both APP/Aβ42 and Aβ42/40 plasma levels with Aβ-PET scan burden and CSF levels of Aβ42, which are more established markers of amyloidosis seen in AD. The use of SIMOA to detect the plasma level of Aβ42/Aβ40 also showed a positive correlation with abnormal CSF level of Aβ42. In terms of prognosis, a lower plasma level of Aβ42/Aβ40 has been shown to be associated with a more rapid decline in cognitive function in patients with subjective cognitive decline.

Another Aβ-related plasma biomarker that has shown prognostic value in AD is the detection of Aβ mis-folding using infrared-sensor technology. In one cohort study, the presence of Aβ mis-folding and Aβ42/Aβ40 plasma levels were tracked in patients with only subjective cognitive decline. The presence of mis-folding and positive Aβ ratios were strongly correlated with the progression to MCI and dementia due to AD.

### Tau

Detecting tau in plasma using immunoassay techniques and using it as a biomarker for AD pathology has shown promise in numerous studies. Several cohorts showed that an increased level of p-tau181 in plasma, as measured by SIMOA and solid-phase enzyme immunoassay, is highly accurate in confirming AD pathology and in differentiating it from other non-AD pathologies in dementia patients. Furthermore, a high plasma p-tau181 level more accurately predicted AD neurupathology compared to clinical diagnosis up to 8 years prior to postmortem examination of brain tissue. An association also exists between a high plasma p-tau181 level and the development of AD dementia in unimpaired patients and those with MCI. This correlates with CSF p-tau181 and is predictive of positive PET scans. Nevertheless, the plasma measurement of p-tau217 shows even more promise. Elevated plasma levels of p-tau217 discriminated AD dementia from other non-AD pathologies with greater accuracy than plasma p-tau181, plasma NfL and the detection of brain atrophy on MRI.

### Neurofilament Light Chain (NfL)

NfLs are components of axons that are another potential biomarker of use in AD. High plasma NfL levels, measured using SIMOA, have been associated with the diagnoses of MCI and AD with Aβ pathology, and are correlated with brain atrophy on neuromaging scans associated with AD. Additionally, plasma NfL has been predictive of the rate of MRI brain atrophy in AD patients when using the Mini-Mental State Examination and Logical Memory Test for assessment. In that same study, serial NfL measurements showed a high rate of change in AD patients when changing from a pre-symptomatic to symptomatic alteration, demonstrating utility in predicting the progression of AD.

### Inflammatory markers

Due to the inflammation involved in the pathogenesis of AD, there are numerous changes in the level of peripheral inflammatory markers, especially IL-1-related cytokines and receptors. Using ELISA, one study found an increase in serum sIL1R2 (soluble interleukin-1 receptor 2) and free IL18 in MCI, which also disappeared in AD. They also found an increase in IL1Ra (interleukin-1 receptor antagonist), sIL1R1, sIL1R4, and IL18BP (interleukin-18 binding protein) in patients with AD but not with MCI, which may aid in showing the progression from MCI to AD. Another peripheral cytokine of possible importance is interleukin-6 (IL6) which was found to be elevated in AD patients compared with healthy controls and showed an inverse correlation with Mini-Mental Status Examination Scores.

Vascular markers

Vascular and microvascular dysregulation has been suggested as a causal role for AD and may precede neurodegeneration with up to 30% of AD cases presenting with cerebrovascular pathology. Many studies have shown elevated levels of soluble E-selectins and VCAM1 in patients with AD compared to healthy controls. Additionally, altered levels of the endothelin regulator and vasodilators endothelin-1 (ET1), atrial natriuretic peptide (ANP), and adrenomedullin (ADM) have been found in AD patients using special immunoassays to detect their precursors. These assays measured C-terminal endothelin-1 precursor fragment (CT-proET1), mid-regional pro-adrenomedullin (MR-proADM), and mid-regional pro-atrial natriuretic peptide (MR-proANP) in the plasma since their final products have short half-lives. In patients with AD, there were increased blood levels of MR-proADM and MR-proANP with decreased levels of CT-proET1. Additionally, both the sensitivity and specificity were increased when measuring the MR-proANP/CT-proET1 ratio. Furthermore, increased plasma levels of MR-proANP and MR-proADM showed predictive value for progression from MCI to AD. It is important to note that these markers might represent systemic microvascular or inflammatory changes, and may warrant further investigation for their clinical utility in diagnosing and predicting AD.

### TAR-DNA binding protein (TDP43)

TDP43 is an RNA and DNA binding protein that is involved in regulating splicing and transcriptional repression, and is a major component of cytoplasmic inclusions within neurons in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It has recently been shown that 25–50% of AD cases present with TDP43 pathological changes, which may be a factor in the development of AD, especially in more severe cases. Increased plasma levels of TDP43 and TDP43 variants have been associated with a higher rate of progression in AD.
detected in both AD and MCI before conversion to AD. Due to increased levels of tDP43 in other neurodegenerative disorders, its clinical utility may be limited in distinguishing between various disorders, but it could still be used to narrow-down potential diagnoses.

**Metabolites**

Dysregulation of several metabolic pathways with changes in plasma metabolites has been associated with and may contribute to AD pathology and impairment. Cholesterol metabolism, fatty acid (FA) metabolism, bile acid synthesis, and amino acid metabolism may be the most associated with AD. Therefore, changes in plasma FAs, bile acids, and amino acids are some of the most apparent alterations reported in previous studies.

The reduction in the level of polyunsaturated fatty acids (PUFA), particularly docosahexaenoic acid (DHA), has been associated with cognitive impairment due to AD and may be due to impaired FA metabolism in the liver. One study showed that cognitive performance improved with dietary supplementation of DHA in AD patients, which could have been due to neuroprotective properties of PUFAs. To further implicated liver dysfunction, the level of the bile acids cholic acid, chenodeoxycholic acid, and allocholic acid all increased with disease severity in AD. The role of bile acids as biomarkers in AD is further propounded by evidence of association between the traditional AD biomarkers, Aβ and tau, and bile acid profiles.

Regarding alterations in FA metabolism, studies have shown declining acyl-carnitines across subjects from healthy individuals to those with MCI and AD, with significantly reduced levels of medium- and long-chain acyl-carnitines in those with AD. Impaired energy metabolism is further indicated by one study that analyzed RNA transcripts to find decreased beta-oxidation, mitochondrial transport, and carnitine shuttle activity in patients with AD.

Amino acid metabolism may also play a role in the use of metabolic profiles as biomarkers of AD, as reduced levels of tryptophan have been found in AD subjects, along with its derivatives of serotonin and indole-3-lactic acid. The decrease in tryptophan and indole-3-lactic acid levels were further associated with disease severity of AD, which may serve as a biomarker for AD disease progression. This follows our physiologic understanding of tryptophan’s role as a precursor for neurotransmitters and their role in neuronal activity.

**Noninvasive biomarkers**

Saliva is an extracellular fluid that functions primarily to aid in the digestion of food and maintain appropriate oral hygiene. It is composed largely of water, and a very minuscule amount of electrolytes, mucus, antibacterial compounds and various enzymes. Salivary testing offers an excellent alternative to expensive laboratory blood tests and invasive CSF measures via lumbar puncture. The most relevant finding has been the elevated salivary cortisol level in AD patients compared to healthy controls. Despite these results, more research is needed before any salivary components can be reliably used as biomarkers in AD and neurodegeneration.

Another potential low-cost biomarker that can be easily collected and stored is a hair sample. Hair is a protein filament composed of keratin that grows from the dermis of the skin. What makes hair follicles a potential biomarker for neurodegenerative disease is the fact that elemental components in its structure can be maintained for extended periods of time. Several elemental metals have been shown to be elevated in AD patients’ hair samples, including Br, K, Na and Zn. By contrast, Al, Ca, Co, Cu, Fe, Hg and Pb levels were reduced in the same hair samples.

Nails are a keratinous plate at the fingertips and toe-tips, and similar to hair, are able to store elemental components for an extended amount of time. Zinc is an abundant element within the brain and may play a role in several pathways relevant to the pathogenesis of AD, most importantly the processing of APP and aggregation of Aβ. The level of zinc and numerous other metal chelators were shown to be decreased in nail samples of patients with AD. However, there is no reliable literature that has consistently linked the use of elemental findings from nail samples as biomarkers in AD, and therefore further analysis is indicated.

The urinary tract may offer the most promise in identifying biomarkers that may distinguish neurodegeneration. Testing urine samples from AD patients is thought to recognize markers or patterns of free radical damage, or oxidative stress that may point to a pathological process of AD. 8-hydroxy-2-deoxy-guanosine (8OHdG) is a major product of DNA oxidative damage and serves as a widely studied biomarker. Previous literature has found elevated 8OHdG levels in the urine by more than ten-fold in AD patients when compared to cognitively normal controls. Isoprostanates and neuroprostanes are prostaglandin-like compounds formed from free radical-catalyzed peroxidation of fatty acids, and are excreted in the urine and may be reliable biomarkers for AD. The level of isoprostanates was shown to be elevated in patients with MCI compared to healthy controls and elevated to a higher extent in AD compared to MCI. Lastly, urinary levels of amino acids are also theorized to be potential biomarkers of AD. Elevated levels of glycine, histidine, 3-methyl histidine and carnosine were isolated in urinary samples of AD patients. While these results demonstrate the increasing use of urine components as biomarkers, the reliability of these components needs further development.

**Iron overload**

Iron plays several important roles within the brain to maintain homeostatic function. Iron is responsible for neuronal oxygen transportation, DNA and myelin synthesis and appropriate mitochondrial functioning. However, iron overload may be detrimental to neuronal health. Previous research has found an increased amount of iron deposits within the brain of patients with AD and MCI. Interestingly, iron facilitated the aggregation of Aβ plaques and p-tau by influencing the function of APP. The utilization of brain imaging (MRI and PET scans) confirmed increased levels of iron in the brain in patients with elevated Aβ deposits, suggesting that iron may accelerate the aggregation of amyloid pathology in this population. Research also points in favor of ferritin as a potential biomarker of AD. Elevated ferritin levels in the CSF have been previously documented in APOE- e4 carriers and reflect a faster cognitive decline in MCI patients as they progress to AD. However, plasma levels of ferritin have not demonstrated a strong correlation with CSF findings in AD and MCI patients. While data is limited on ferritin as a biomarker, it may be more useful as a prognostic marker in the CSF when evaluating AD.
Prospect

Medical advancements and drug therapy trials targeting neurodegeneration have largely failed to provide any significant advancement in the detection, treatment, and prevention of neurodegeneration. AD treatment is tending in the direction of a precision-based model to individualize diagnostic algorithms and treatment plans. By incorporating the accuracy and reliability of more physiological biomarkers, we may be able to better understand the patient population at higher risk for neurodegeneration and slow disease progression. Individualized biomarkers in AD and other neurodegenerative diseases may provide a path towards prevention and potential curative measures.

Conclusions

Biomarkers have played a crucial role in improving the diagnostic efficiency, cost analysis, and overall enhancement of our understanding of the pathophysiology in neurodegeneration. Biomarker inclusion has remained an overwhelming target in AD research, with the most reliable and widely studied ones comprising amyloid and tau pathology. More data is needed to standardize and stratify biomarkers indicating vascular pathology, neuro-inflammatory response, and reliable noninvasive markers outside of the blood and CSF.

Acknowledgments

We thank Kimberly Castellano for designing and creating the image represented in Figure 1.

Funding

This work did not receive funding for the development or writing of this manuscript.

Conflict of interest

The authors have no financial conflicts of interest or conflicts of any interests to disclose.

Author contributions

Study concept and design (JK), acquisition of data (VM, JK), manuscript writing (VM, JK), critical revision of the manuscript for important intellectual content (VM, JK), analysis and interpretation of data (VM, JK).

References

[1] Cass SP. Alzheimer’s Disease and Exercise: A Literature Review. Curr Sports Med Rep 2017;16(1):19–22. doi:10.1249/JSR.0000000000000332.
[2] Tarawneh R. Biomarkers: Our Path Towards a Cure for Alzheimer Disease. Biomark Insights 2020;15:1177271920976367. doi:10.1177/1177271920976367.
[3] The Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement 2021;17(3):327–406. doi:10.1002/alz.1235.
[4] Rajan KB, Weuve J, Barnes LL, McNainch EA, Wilson RS, Evans DA. Population estimate of people with clinical AD and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement 2021;17. In press.
[5] Shao Y, Ouyang Y, Li T, Liu X, Xu X, Li S, et al. Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer’s Disease. Aging Dis 2020;11(6):1459–1470. doi:10.14336/AD.2020.0217.
[6] Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1(1):a006189. doi:10.1101/cshperspect.a006189.
[7] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239–259. doi:10.1007/BF003 08809.
[8] Kinney JW, Bemiller SM, Murtishaw AS, Leigang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement 2018;4:575–590. doi:10.1016/j.trci.2018.06.014.
[9] Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 1997;23(1):134–147. doi:10.1016/S0891-5849(96)00629-6.
[10] Sderlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis 2018;62(3):1403–1416. doi:10.3233/ JAD-170585.
[11] Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer’s disease. J Alzheimers Dis 2017;57(4):1041–1048. doi:10.3233/ JAD-160763.
[12] Chen Y, Fu AKY, Ip NY. Synaptic dysfunction in Alzheimer’s disease: Mechanisms and therapeutic strategies. Pharmacol Ther 2019; 195:186–198. doi:10.1016/j.pharmthera.2018.11.006.
[13] Bature F, Guinn BA, Pang D, Pappas Y. Signs and symptoms preceding the diagnosis of Alzheimer’s disease: a systematic scoping review of literature from 1937 to 2016. BMJ Open 2017;7(8):e015746. doi:10.1136/bmjopen-2016-015746.
[14] Bayer AI. The role of biomarkers and imaging in the clinical diagnosis of dementia. Age Ageing 2018;47(5):641–643. doi:10.1093/ageing/afy004.
[15] Xu KH, Huang Y, Wang G, Chen SD. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer’s disease. Neurosci Bull 2012;28(5):641–8. doi:10.1007/s12264-012-1272-0.
[16] Gremel L, Schölzel D, Schenk C, Reintez E, Labahn J, Ravelli RBG, et al. Fibril structure of amyloid-ß(1-42) by cryo-electron microscopy. Science 2017;358(6359):116–119. doi:10.1126/science.aao2825.
[17] Uddin MS, Kabir MT, Rahman MS, Behl T, Jelandt P, Ashraf GM, et al. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease. Int J Mol Sci 2020;21(6):5858. doi:10.3390/ijms21165858.
[18] Zhang H, Zheng Y. Amyloid Hypothesis in Alzheimer’s Disease: Pathogenesis, Prevention, and Management. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2019;41(5):702–708. doi:10.3881/j.issn.1000-503X.10875.
[19] DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990;27(5):457–464. doi:10.1002/ana.410270502.
[20] Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Denritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer’s Disease Mouse Models. Cell 2010;142(3);387–397. doi:10.1016/j.cell.2010.06.036.
[21] Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neuosci 2007;8(9):663–672. doi:10.1038/nrn2194.
[22] Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci 2014;8:113. doi:10.3389/fncel.2014.00113.
[23] Iba M, Guo J, McBride JD, Zhang B, Trojanowski JQ, Lee VMY. Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer’s-Like Tauopathy. J Neurosci 2013;33(3);1024–1037. doi:10.1523/JNEUROSCI.2642-12.2013.
[24] Reitz C, Mayeux R. Alzheimer disease: Epidemiology, Diagnostic Criterias, Risk Factors and Biomarkers. Biochem Pharmacol 2014; 88(4):640–651. doi:10.1016/j.bcp.2013.12.024.
[25] Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW,
et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Trans Med 2011;3(89):B9ra57. doi:10.1126/scitransmed.3002156.

[26] Wegen S, Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res Ther 2012;4(2):9. doi:10.1186/alzrt107.

[27] Hirsch MS, Watkins J. A comprehensive review of biomarker use in the gynecologic tract including differential diagnoses and diagnostic pitfalls. Adv Anat Pathol 2020;27(3):164–192. doi:10.1097/PAP.0000000000000238.

[28] Tapiola T, Alafuzoff I, Herukka SK, Parkkinnen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid (beta)-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathological changes in the brain. Arch Neurol 2009;66(3):382–389. doi:10.1001/archneur.2008.596.

[29] Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, Weggen S, Beher D. Biomarkers of Alzheimer's disease in cerebrospinal fluid (beta)-amyloid peptide and presenilin mutations causing autosomal-dominant Alzheimer's disease. J Neurochem 2009;108(1):274–285. doi:10.1111/j.1471-4159.2008.05792.x.

[30] Andreasen N, Minton L, Davidson P, Vannemdeelen E, Vanderstichele H, Blennow K, Hampel H. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016;15(7):673–684. doi:10.1016/S1474-4422(16)30070-3.

[31] Moore J, Faria S, Prusty SK, Sahu PK. CSF and blood biomarkers for Alzheimer's disease: a review. Sys Rev Pharm 2020;11(6):151–158. doi:10.31838/srp.2020.6.24.

[32] Olsson F, Vannemdeelen E, Vanderstichele H, Blennow K, Hampel H. CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256(3):224–234. doi:10.1111/j.1365-2796.2004.01368.x.

[33] Vassar R, Bennett BD, Abu-Bakr S, Kahn S, Mendizabal E, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286(5440):735–741. doi:10.1126/science.286.5440.735.

[34] Decourt B, Gonzales A, Beach TG, Malek-Ahmadi M, Walker A, Sue L, Wolkers S, Welling A, Levesque S, Vanderstichele H, Lindberg O, et al. CSF Ab42/Ab40 and Ab42/Ab38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neuro 2016;3(3):154–165. doi:10.1002/acn3.274.

[35] Wittflog I, Esselmann H, Bibi M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospha-Tau in patients with low- and high-CSF Aβ42 load. J Neurochem 2007;101(4):1053–1059. doi:10.1111/j.1471-4159.2006.04404.x.

[36] Gervaise-Henry C, Watfa G, Albusseau E, Kolodziej A, Dousse A, Olivier BI, et al. Cerebrospinal Fluid β42/α40 as a Means to Limiting Tube and Storage Dependent Pre-Analytic Variability in Clinical Settings. J Alzheimers Dis 2017;57(5):437–445. doi:10.3233/JAD-160865.

[37] Kennedy ME, Stanford AW, Chen X, Cox K, Cumming JN, Dackord MF, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med 2016;8(363):363ra150. doi:10.1126/scitransmed.aad9704.

[38] Olsson F, Schmidt S, Attho V, Munter LM, Jin S, Rosqvist S, et al. Characterization of intermediate steps in amyloid beta (Ab) production under near-native conditions. J Biol Chem 2014;289(3):1540–1550. doi:10.1074/jbc.M113.498246.

Marcucci V. et al. A review of biomarkers in Alzheimer’s disease.
Marcucci V, et al. A review of biomarkers in Alzheimer’s disease

Explor Res Hypothesis Med

DOI: 10.14218/ERHM.2021.00016  |  Volume 00 Issue 00, Month Year 11
Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 1985;8(4-6):203–214. doi:10.1016/S0165-5728(85)80063-1.

Betke H, Kasaí T, Ohnishi T, Kishi Y, Kakeya T, Waragai M, et al. Quantification of plasma phosphorylated tau to use as a biomarker for Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome. Mol Neurodegener 2017;12(1):63. doi:10.1186/s13024-017-0206-8.

Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuroapathy and longitudinal progression to Alzheimer’s dementia. Nat Med 2020;26(3):379–386. doi:10.1038/s41591-020-0755-1.

Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Loperå F, Stromrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 2020;324(8):772–781. doi:10.1001/jama.2020.12134.

Mattsson N, Andresson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light With Neuroinflammation in Patients With Alzheimer Disease. JAMA Neurol 2017;74(5):557–566. doi:10.1001/jamaneurol.2016.6117.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 2019;25(2):277–283. doi:10.1038/s41591-018-0304-3.

Ittavik P, Puxeddu J, Napoleon S, Scala E, Melillo D, Manocchio S, et al. Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression? J Neuroinflammation 2018;15(1):342. doi:10.1186/s12974-018-1376-1.

Lai KSP, Liu CS, Rau A, Lanctôt KL, Köhler CA, Pakosh M, et al. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry 2017;88(10):876–882. doi:10.1136/jnnp-2017-316201.

Gate D, Saligramana N, Leventhal O, Yang AC, Unger MS, Middeldorp J, et al. Clinically expanded CSF T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 2020;577(7790):399–404. doi:10.1038/s41586-019-1895-7.

Tian J, Town T, Abdullah L, Wu Y, Placzek A, Small B, et al. CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer’s disease. J Neuroinflammation 2020;17(1):164–172. doi:10.1186/s12974-020-01319-1.

Reza-Zadeh K, Gate D, Szekely CA, Town T. Can peripheral leukocytes be used as Alzheimer’s disease biomarkers? Expert Rev Neurother 2009;9(11):1623–1633. doi:10.1586/erm.09.118.

Ewers M, Mielke MM, Hampel H. Blood-based Biomarkers of Vascular Disease: A Systematic Review and Meta-analysis of 135 Studies. Stroke 2020;51(4):931–940. doi:10.1161/STR.0000000000000371.

Vilarino-Guell C, Paraddock K, Ross GW, et al. Cerebrospinal fluid amyloid-β and total tau biomarkers of cognitive decline in Alzheimer’s disease. Neurology 2019;93(17):e1647–e1659. doi:10.1212/WNL.0000000000008081.

Marcucci V, et al. A review of biomarkers in Alzheimer’s disease

[110] Tarkowski E, Andreassen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003;74(9):1200–1205. doi:10.1136/jnnp.74.9.1200.

[111] Verberk IMW, Hendriksen HMA, van Harten AC, Wesselman LMP, Verfaille SCJ, van den Bosch KA, et al. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiol Aging 2020;89:99–107. doi:10.1016/j.neurobiolaging.2020.01.007.

[112] Verberk IMW, Slot RE, Verfaille SCJ, Heijst H, Prins ND, van Berckel NM, et al. Plasma Amyloid as Precursor for the Earliest Alzheimer Pathological Changes. Ann Neurol 2018;84(5):648–658. doi:10.1002/ana.25334.

[113] Stockmann J, Verberk IMW, Timmesfeld N, Denz R, Budde B, Lange-Leihmann J, et al. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline. Alzheimers Res Ther 2020;12(1):169. doi:10.1186/s13195-020-00738-8.

[114] Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, Troakes C, King A, Emerisc A, et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 2020;140(3):267–278. doi:10.1007/s00401-020-02195-x.

[115] Tutebe H, Kasai T, Ohnishi T, Kishi Y, Kakeya T, Waragai M, et al. Quantification of plasma phosphorylated tau to use as a biomarker for Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome. Mol Neurodegener 2017;12(1):63. doi:10.1186/s13024-017-0206-8.

[116] Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuroapathy and longitudinal progression to Alzheimer’s dementia. Nat Med 2020;26(3):379–386. doi:10.1038/s41591-020-0755-1.

[117] Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Loperå F, Stromrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 2020;324(8):772–781. doi:10.1001/jama.2020.12134.

[118] Mattsson N, Andresson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light With Neuroinflammation in Patients With Alzheimer Disease. JAMA Neurol 2017;74(5):557–566. doi:10.1001/jamaneurol.2016.6117.

[119] Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 2019;25(2):277–283. doi:10.1038/s41591-018-0304-3.
thaler NG, et al. Blood-based microcirculation markers in Alzheimer’s disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Bio Psychiatry 2009;65(11):979–984. doi:10.1016/j.biopsych.2009.01.032.

[137] Buergier K, Uspenskaya G, Hartmann O, Hansson O, Minthon L, Bleanow K, et al. Prediction of Alzheimer’s disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J Clin Psychiatry 2011;72(4):556–563. doi:10.4088/JCP.m09m58720l.

[138] Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;331(3):602–611. doi:10.1016/j.brc.2006.10.093.

[139] Wilson AC, Dugger BN, Dickson DW, Tang DP. TDP-43 in aging and Alzheimer’s disease—a review. Int J Clin Exp Pathol 2011;4(2):147–155.

[140] Huang W, Zhou Y, Tu L, Bu Z, Huang J, Huang N, et al. TDP-43: From Alzheimer’s Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy. Front Mol Neurosci 2020;13:26. doi:10.3389/fnmol.2020.00026.

[141] Foulds P, McCauley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D, et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration. Acta Neuropathol 2008;116(2):141–146. doi:10.1007/s00401-008-0389-8.

[142] Tomé SO, Vandenberge R, Opsitniker S, Van Schoor E, Tousseny T, Otto M, et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes. Acta Neuropathol Commun 2020;8(1):61. doi:10.1038/s41478-020-00394-5.

[143] Williams SM, Schulz P, Rosenberry TL, Caselli RJ, Siersk MR. Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer’s Disease. J Alzheimers Dis 2017;58(1):23–35. doi:10.3233/JAD-161116.

[144] Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, O’Brien R, et al. Altered Bile Acid Profile in Mild Cognitive Impairment in Healthy Elderly Community Dwellers in Japan. BMC Geriatr 2017;17(1):239. doi:10.1186/s12877-017-0639-5.

[154] Roberts KB. Essentials of Human Physiology. Can Med Assoc J 1979;121(3):335–336.

[155] Giubilei F, Patacchioli FR, Antonini G, Monti MS, Tisei P, Bastianello S, et al. Altered circadian cortisol secretion in Alzheimer’s disease: clinical and neuropsychological aspects. J Neurosci Res 2001;66(2):262–265. doi:10.1002/jnr.1219.

[156] Sinclair RD. Healthy hair: what is it? J Invest Dermatol Symp Proc 2007;12(2):2–5. doi:10.1038/jj.isymp.5650046.

[157] Koseoglu E, Koseoglu R, Kendirci M, Saraymen R, Saraymen B. Trace metal concentrations in hair and nails for Alzheimer’s disease patients with clinical severity. J Trace Elem Exp Med 2017;39:124–128. doi:10.1016/j.jtem.2016.09.002.

[158] de Berker D. Nail anatomy. Clin Dermatol 2013;31(5):509–515. doi:10.1016/j.clindermatol.2013.06.006.

[159] Lovell MA. A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer’s disease. J Alzheimers Dis 2009;16(3):471–483. doi:10.3233/JAD-2009-0992.

[160] de Souza-Pinto NC, Eide L, Hague BA, Thoby T, Stevensner T, Seeberg E, et al. Repair of 8-oxodeguanosine lesion and plasma paraoxonase 1 activity depends on the oxoguanine dna glycosylase (OGG1) gene and 8-oxoguanine accumulates in the mitochondrial dna of OGG1-defective mice. Cancer Res 2001;61(4):5378–5381.

[161] Zengi O, Karakas A, Ergun U, Senes M, Inan L, Yucel D. Urinary 8-hydroxy-2'-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer’s disease. Chem Clin Lab Med 2011;50(3):529–534. doi:10.1515/CCLM.2011.792.

[162] Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18(15):1791–1800. doi:10.1096/fj.04-2339fwe.

[163] Tang Z, Liu L, Li Y, Dong J, Li M, Huang J, et al. Urinary Metabolomics Reveals Alterations of Aromatic Acid Metabolism of Alzheimer’s Disease in the Transgenic CRND8 Mice. Curr Alzheimer Res 2016;13(7):764–776. doi:10.2174/1567205013666160129095340.

[164] Socha E, Koba M, Kosiński P. Amino acid profiling as a method of discovering biomarkers for diagnosis of neurodegenerative diseases. Amino Acids 2019;51(3):367–371. doi:10.1007/s00726-019-02705-6.

[165] Molinuerto JL, Ayton S, Batra R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol 2018;136(6):821–853. doi:10.1007/s00401-018-1932-x.

[166] Ward RJ, Zucca FA, Duyh JH, Crichton RR, Zucca L. The role in iron brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study. PLoS Med 2017;14(3):e1002266. doi:10.1371/journal.pmed.1002266.

[167] Tynkkynen J, Chouraki V, van der Lee SJ, Hresnesniemi J, Yang Q, Li S, et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: A prospective study in eight cohorts. Alzheimers Dement 2018;14(6):723–733. doi:10.1016/j.jalz.2018.01.003.

[168] Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014;20(4):415–418. doi:10.1038/nm.3466.

[169] Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier C, Looi CL, et al. Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer’s Disease. PLoS One 2010;5(9):e12538. doi:10.1371/journal.pone.0012538.

[170] Swanson D, Block R, Moussa SA. Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life. Adv Nutr 2012;3(1):1–7. doi:10.3945/an.111.008939.

[171] Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, et al. Altered Bile Acid Profile in Mild Cognitive Impairment and Alzheimer’s Disease: Relationship to Neuroimaging and CSF Biomarkers. Alzheimers Dement 2019;15(2):232–244. doi:10.1016/j.jalz.2018.08.017.

[172] Giubilei F, Patacchioli FR, Antonini G, Corbi G, et al. Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer’s Dementia. PLoS One 2016;11(5):e0155694. doi:10.1371/journal.pone.0155694.

[173] Stempeler S, Yihak K, Ruppin E. Integrating Transcriptomics with Metabolomic Data to Predict Biomarkers for Alzheimer’s Disease. PLoS One 2014;9(8):e105383. doi:10.1371/journal.pone.0105383.

[174] Adachi Y, Shimoda Y, Nakamura H, Imaizumi A, Mori M, Kageyama Y, et al. Low plasma tryptophan is associated with olfactory function in healthy elderly community dwellers in Japan. BMC Geriatr 2017;17(1):239. doi:10.1186/s12877-017-0639-5.